PURPOSE: To evaluate @entity1349 ( @entity1349 ), progression-free survival (PFS), loco-regional recurrence (LRR), and @entity137 for early @entity0 @entity1 with one to three positive axillary lymph nodes, by the addition of radiotherapy to adjuvant chemotherapy. @entity1 AND METHODS: @entity1 were eligible for enrollment into the study if they had pathologically proven stages II @entity0 , with one to three positive axillary lymph nodes. @entity1 were assigned to one of the two groups; Group 1; adjuvant chemotherapy then radiotherapy, and group 2; adjuvant chemotherapy only. RESULTS: Between September 2008 and August 2014, 75 @entity1 were enrolled. Forty @entity1 group 1, and 35 group 2. The 4-year @entity1349 for group 1, and two were 77.5 and 71.4%, respectively. The 4-year PFS for group 1 and 2 were 72.5 and 60%, respectively. During the 54   months follow-up period, 11 @entity1 from group 1 had recurrence (three locoregional, seven metastatic, and one both), and 14 @entity1 from group 2 had recurrence (seven locoregional, three metastatic, and four both). The distant @entity3 rate was the same in the two groups. However, the @entity3 sites were different in the two groups. CONCLUSION: The addition of radiotherapy in @entity0 with one to three positive lymph nodes improved the PFS, and LRR. Radiotherapy improved @entity1349 in @entity1 with high-risk features.

For Stage II Node-Positive XXXX , is it Worthwhile to Consider Adjuvant Radiotherapy Following Mastectomy?

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast-cancer', 'stage II breast cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity0 :: (MESH:D001943,Disease) :: ['Breast Cancer']
